ASHBURN, Va., June 27, 2025 /PRNewswire/ -- DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, today announced the official opening of its office in Farnborough, a state-of-the-art location that is home to DXC's dedicated Aerospace and Defense Hub. This milestone follows the recent opening of DXC's first office in Toronto and is part of the company's broader growth strategy, reinforcing its commitment to talent, innovation, and customer success across the globe.
DXC's new Farnborough location is a purpose-built, technology enabled environment that fosters connection, collaboration, and innovation among employees and new and existing customers. With a presence in the UK for over four decades, DXC employs more than 6,500 people nationwide. The site brings together teams from Aldershot and Hook into a single location and is expected to create opportunities for the local workforce - including armed forces veterans and reservists, as well as graduate, apprentice, and early-careers opportunities through the DXC UKI Academic Programme.
"Farnborough is a storied and vibrant destination for innovators and world-class businesses," said Councillor Calum Stewart, Mayor of Rushmoor. "We are pleased to welcome DXC as part of our community and applaud their commitment to investing in local talent and creating new opportunities for the next generation of professionals. We wish them much success in the years to come."
"The launch of our Farnborough office marks an exciting new chapter for DXC in the UK, bringing together our employees and customers across all industries to build bold, future-ready solutions," said Cameron Art, DXC President of the Americas and UKI. "Our new Aerospace and Defense Hub underscores our commitment to this sector and positions us to help shape the future of innovation for some of the world's leading private and public sector aerospace and defense organizations."
Farnborough has a long-standing reputation as a center for aviation, engineering, and technology. For over 50 years, DXC's mission-critical solutions have kept dozens of ministries, defense agencies, and armed services organizations worldwide operating smoothly and cost-effectively. The new Farnborough Aerospace and Defense Hub, strategically chosen to strengthen partnerships in the area, will have dedicated resources to invest in innovation and collaboration in the sector.
The Farnborough opening is part of a broader series of strategic growth initiatives for DXC across the Americas and UKI. The company recently opened its first office in Toronto and is expanding offices in New York City, Miami, and London, further enhancing its ability to serve customers and foster collaboration and co-creation.
For more information, visit www.dxc.com.
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission-critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. The world's largest companies and public sector organizations trust DXC to deploy services to drive new levels of performance, competitiveness, and customer experience across their IT estates. Learn more about how we deliver excellence for our customers and colleagues at DXC.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
DXC Opens Farnborough Office, Launches Aerospace and Defense Hub in the UK
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
